ALBANY, N.Y., May 17, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) announced today the launch of the first member of its new generation of peripherally inserted central catheters (PICCs) for procedures involving the use of contrast media in computed tomography (CT) - the Morpheus Smart PICC Triple Lumen CT PICC.
"This not only marks the first product to launch in our new Morpheus Smart PICC line, as a triple lumen it complements our existing offerings and ensures we can meet the full range of physicians' needs," said Robert Rossell, Senior Vice President and General Manager for AngioDynamics' Vascular Access Business Unit.
The product features the key benefits of AngioDynamics' new Morpheus Smart PICC generation of products, Smart Taper™ catheter technology and a minimally-invasive design.
The Smart Taper technology allows the catheter to quickly taper from a seven French diameter to a precise six French diameter, improving blood flow and reducing the risk of thrombosis. The PICC's catheter shaft technology couples the pushability needed for PICC placement with pliability that minimizes the risk of vessel trauma and phlebitis.
The new PICC has three distinct tubular channels, or lumens, which give practitioners increased flexibility to administer medications simultaneously and perform power injections of contrast media for CT imaging using a single PICC line.
For more information on the Morpheus Smart PICC Triple Lumen CT PICC, visit the AngioDynamics Web site at www.angiodynamics.com/products/morpheus-smart-picc.
AngioDynamics, Inc. is a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
SOURCE: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
EVC Group, Inc. (Investor Relations)
Doug Sherk, 415-896-6820
Jenifer Kirtland, 415-896-6820
EVC Group, Inc. (Media)
Chris Gale, 646-201-5431
Copyright Business Wire 2010